Aldeyra Therapeutics
ALDX
108 hedge funds and large institutions have $353M invested in Aldeyra Therapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
53% more capital invested
Capital invested by funds: $232M → $353M (+$122M)
52% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 25
14% more funds holding
Funds holding: 95 → 108 (+13)
3.87% more ownership
Funds ownership: 56.85% → 60.72% (+3.9%)
4% less call options, than puts
Call options by funds: $5.23M | Put options by funds: $5.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.11M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.02M |
| 3 |
N
Natixis
Paris,
France
|
+$4.46M |
| 4 |
Millennium Management
New York
|
+$1.9M |
| 5 |
Goldman Sachs
New York
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$4.36M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.69M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$3.36M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.74M |
ALDX Hedge Fund Activity: Q1 2023 in Review
108 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2023, worth a combined $353M — up 53% from $232M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ALDX positions and 8 closed out — a net gain of 13 holders — while 38 added to existing stakes and 25 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.11M. The largest seller was J. Goldman & Co, cutting an estimated $4.36M.
- 108 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2023, up from 95 in Q4 2022.
- Funds reported $353M of Aldeyra Therapeutics stock for Q1 2023, up 53% quarter-over-quarter.
- 21 funds opened new Aldeyra Therapeutics positions in Q1 2023 and 8 closed out, a net change of +13 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $6.11M added.
- The largest Aldeyra Therapeutics seller in Q1 2023 was J. Goldman & Co, an estimated $4.36M sold.
Based on aggregated 13F filings for Q1 2023.